A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 186 600 KRW 2.47%
Market Cap: 10.3T KRW

Net Margin
ABL Bio Inc

-21.6%
Current
-93%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-21.6%
=
Net Income
-20.5B
/
Revenue
94.9B

Net Margin Across Competitors

No Stocks Found

ABL Bio Inc
Glance View

ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.

Intrinsic Value
16 181.71 KRW
Overvaluation 91%
Intrinsic Value
Price
A
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-21.6%
=
Net Income
-20.5B
/
Revenue
94.9B
What is the Net Margin of ABL Bio Inc?

Based on ABL Bio Inc's most recent financial statements, the company has Net Margin of -21.6%.

Back to Top